Clotting Factor Concentrates – Whither Purity?

• References

• 1 Mannueci PM. Effects of Factor VIII concentrates on the immune system of patients with hemophilia. Thromb Haemost 1995; 74: 437-439
• 2 de Biasi R, Rocino A, Miraglia E, Mastrullo L, Quirino AA. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized prospective two year comparison with an intermediate purity concentrate. Blood 1991; 78: 1918-1922
• 3 Seremitis S, Aledort LM, Bergman G, Bona R, Bray G, Brettler DB, Eyster ME, Kessler C, Lan TS, Lusher JM, Rickerts F. Three-year randomized study of high-purity or intermediate purity factor VIII concentrates in symptom-free HIV-seropositive hemophiliacs: effect on immune status. Lancet 1993; 342: 700-703
• 4 Brettler BD, Forsberg AD, Levine PH, Petillo J, Lamon K, Sullivan JL. Factor VIIL:C concentrate purified from plasma using monoclonal antibodies: human studies. Blood 1989; 73: 1859-1863
• 5 Goldsmith JM, Deutsche J, Tany M, Green D. CD4 eells in HIV-1 infected hemophiliacs: effect of factor VIII concentrates. Thromb Haemost 1991; 66: 415-419
• 6 Hilgartner M, Buckley JD, Operskalski EA, Pike MC, Mosley JW. Purity of factor VIII concentrates and serial CD4 counts. Lancet 1993; 341: 1373-1374
• 7 Sabin C, Pasi J, Phillips A, Elford J, Janossy G, Lee C. CD4+ counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilie patients. Thromb Haemost 1994; 72: 214-217
• 8 Gjerset GF, Pike MC, Mosley JW, Hassett J, Fleteher MA, Donegan E, Parker JW, Counts RB, Zhou Y, Kasper CK, Operskalski EA. and the Transfusion Safety Study Group. Effect of low- and intermediate-purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. Blood 1994; 84: 1666-1661
• 9 Berntorp E. Impact of replacement therapy on the evaluation of HIV infection in hemophiliacs. Thromb Haemost 1994; 71: 678-673
• 10 Varon D, Schulman S, Dardik R, Barzilai A, Bashari D, Martinowitz U. High versus ultra-high purity Factor VIII concentrate therapy: prospective evaluation of immunological and clinical parameters in HIV seronegative and seropositive hemophiliacs. Thromb Haemost 1994; 72: 359-362
• 11 Evans JA, Pasi KJ, Williams MD, Hill FG H. Consistently normal CD4+, CD8+ levels in haemophilie boys only treated with a virally safe factor VIII concentrate (BPL 8Y). British Journal of Haematology 1991; 78: 457-461
• 12 Study group of the UK haemophilia Centre Directors on surveillance of virus transmission by concentrates. Effect of dry-heating of coagulation factor concentrates at 80C for 72 hours on transmission of non-A, non-B hepatitis. Lancet 1988; 2: 814-816
• 13 Rizza CR, Fletcher ML, Kernoff PB A. Confirmation of viral safety of dry heated factor VIII concentrate (8Y) prepared by BioProducts Laboratory (BPL): a report on behalf of UK Haemophilia Centre Directors. British Journal of Haematology 1993; 84: 269-272
• 14 Williams MD, O’Brien S, Hill FG H. Prospective study of the frequency of factor VIII inhibitor formation following the use of a single heat treated intermediate purity concentrate (BPL 8A) in haemophilie boys. British Journal of Haematology 1994; 86: 59
• 15 Colvin BT, Hay CR M, Hill FG H, Preston FE. The incidence of factor VIII inhibitors in the United Kingdom, 1990-93. British Journal of Haematology. 1995. 89 908-910
• 16 Data on file. Bio Products Laboratory; Elstree, Herts, UK:
• 17 Schimpf K, Schwarz HP, Kunschak M. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Thromb Haemost 1995; 73: 553-554
• 18 Wadhwa M, Dilger P, Tubbs J, Mire-Sluis A, Barrowcliffe T, Thorpe R. Identification of transforming growth factor-β as a contaminant in Factor VIII concentrates: a possible link with immunosuppressive effect in hemophiliacs. Blood 1994; 84: 2021-2030
• 19 Menache D, Behre HE, Orthner CL, Nunez H, Anderson HD, Triantaphllo-poulos CD, Kosow D. Coagulation factor IX concentrate: method of preparation and assessment of potential in vivo thrombogenicity in animal models. Blood 1984; 64: 1220-1227
• 20 Lusher JM. Thrombogenicity associated with factor IX concentrates. Seminars in Hematology 1991; 28: 3-5
• 21 Mannucci PM, Bauer KA, Gringeri A, Bazegar S, Santagostino E, Tradati FC, Rosenberg RD. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 1990; 76: 606-611
• 22 Mannucci PM, Bauer KA, Gringeri A, Bazegar S, Santagostino E, Tradati FC, Rosenberg RD. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. Br J Haematol 1991; 79: 606-601
• 23 Hampton KK, Preston FE, Lowe GD O, Walker ID, Sampson B. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate. Br J Haematol 1993; 84: 279-284
• 24 Thomas DP, Hampton KK, Dasani H, Lee CA, Giangrande PL F, Harman C, Lee ML. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate. Br J Haemat 1994; 87: 782-788
• 25 Nilsson IM. Experience with prophylaxis in Sweden. Semin Hemat 1993; 30 Suppl (Suppl. 02) 16-19